SLC5A2 and type 2 diabetes mellitus: We also reported that the administration of the SGLT2 inhibitor luseogliflozin preserved the renal function and reduced the blood pressure, body weight and urinary protein excretion (uPE) in type 2 diabetic patients with an eGFR of <60 mL/min/1.73 m2 without increased adverse events (AEs) specific for SGLT2 inhibitors [11].